Business
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board
- Dr. MacMichael brings over 35 years of experience in development and manufacture of therapeutic proteins, vaccines, and cell and gene therapies -- Dr.
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"- Dr. MacMichael brings over 35 years of experience in development and manufacture of therapeutic proteins, vaccines, and cell and gene therapies -- Dr. MacMichael to play key role in guiding cell therapy CMC to advance XCART™ Platform -FRAMINGHAM, MA / ACCESSWIRE / February 26, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today it has bolstered its product development expertise with the appointment of Greg MacMichael, Ph.D. to its Scientific Advisory Board (\"SAB\").\"We are pleased to welcome Dr. MacMichael to our SAB and to have the opportunity to leverage his extensive cell therapy CMC expertise as we work to develop the XCART™ platform. He has established a proven track record in the successful planning and execution of drug development and production over the course of his career and is a key addition to our team,\" commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic. \"As we execute on our preclinical development strategy, it is important that we pay close attention to manufacturing processes, which is particularly critical for complex cell therapy products, and an area of expertise Dr. MacMichael has developed over the course of his career. I believe the leadership and expertise that Dr. MacMichael brings will be integral in how we shape and advance the development program of XCART™ moving forward.\"Since 2010, Greg MacMichael, Ph.D., has served as the President and Founder of CMC BioServices, LLC, a well-established consulting firm through which he has assisted innovators and biopharmaceutical companies with successful development and licensure of cell and gene therapies, biologics and vaccines. Dr. MacMichael most recently served as the Senior Vice President of Technical Operations at Axovant Gene Therapies where he oversaw the manufacturing of Axovant's pipeline of gene therapies. Over the course of his 35 years of experience in biopharmaceuticals, Dr. MacMichael held positions such as Senior Vice President of Development, Manufacturing and Quality Control at NantKwest Therapeutics and Senior Vice President of Process, Development, Manufacturing and Quality Assurance at Rocket Pharma. Additionally, he pr...